On February 5, 2014 Pfizer reported that it has agreed with Merck & Co to explore the therapeutic potential of Merck’s investigational anti-PD-1 therapy, MK-3475, in combination with two Pfizer oncology assets (Press release , FEB 5, 2014, View Source [SID:1234500283]). A Phase I/II clinical study will evaluate the safety and anti-cancer efficacy of MK-3475 combined with Pfizer’s axitinib. A separate Phase I study will evaluate the safety and tolerability of the combination of MK-3475 and PF-05082566 (PF-2566).
Pfizer will conduct the clinical studies of MK-3475 plus axitinib and MK-3475 plus PF-2566. This agreement does not provide for any collaboration between Pfizer and Merck following the completion of the specified studies.
Financial terms were not disclosed.
Under a separate agreement Pfizer and Merck are currently exploring the pre-clinical combination of MK-3475 with Pfizer’s investigational therapy palbociclib (PD-0332991). Merck is conducting these pre-clinical studies. Further studies would depend on the outcome of the ongoing pre-clinical studies as well as subsequent agreement by Merck and Pfizer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

(Press release, Bayer, FEB 4, 2014, View Source;parent=news-overview-category-search-en&ccm=800010 [SID:1234505761])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

(Press release GW Pharmaceuticals, FEB 4, 2014, View Source [SID:1234501598])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On February 3, 2014 OncoTherapy Science reported that the patient enrollment in the Phase II clinical study of cancer peptide vaccine S-588410, which contains five oncoantigen peptides and outlicensed to Shionogi&Co., Ltd, in bladder cancer patients has been commenced in Japan and Europe, as released by Shionogi today (Press release OncoTherapy Science, FEB 3, 2014, View Source [SID:1234500732]). This clinical study is to evaluate the clinical effect of S-588410 when administered to the bladder cancer patients.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

S-588410 is a mixed peptide cocktail vaccine of S-288310, for which Shionogi has already conducted a clinical study, and S-488310 (BSG NOTE: Possibly S-488410?), and is expected to have an advanced efficacy.

OncoTherapy has decided to leave fiscal 2013 full-year forecasts announced on 31th January,2014 unchanged.

On February 3, 2014 Pfizer reported that the randomized Phase II trial [PALOMA-1] (NCT00721409) of palbociclib achieved its primary endpoint by demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for the combination of palbociclib and letrozole compared with letrozole alone in post-menopausal women with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or newly diagnosed metastatic breast cancer (Press release Pfizer, FEB 3, 2014, View Source [SID:1234500282]).
Adverse events observed for the palbociclib arm were consistent with the known adverse event profile for this combination. Detailed efficacy and safety data from PALOMA-1 will be submitted for presentation at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2014 scheduled for April 5-9th in San Diego.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!